Galectin-1 as an oncotarget in gliomas and melanomas.

Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis. Oncotarget (2013) 0.88

Melanoma Cell Galectin-1 Ligands Functionally Correlate with Malignant Potential. J Invest Dermatol (2015) 0.78

Galectins as modulators of tumour progression. Nat Rev Cancer (2005) 5.30

Apoptosis of T cells mediated by galectin-1. Nature (1995) 3.54

Galectin-1: a small protein with major functions. Glycobiology (2006) 3.06

Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell (2004) 2.46

Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A (2006) 2.26

Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res (2010) 1.50

Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol (2008) 1.05

Tolerogenic dendritic cells in the control of autoimmune neuroinflammation: an emerging role of protein-glycan interactions. Neuroimmunomodulation (2010) 0.89

Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior. World J Biol Chem (2011) 0.84

Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol (2005) 3.46

Galectin-1: a small protein with major functions. Glycobiology (2006) 3.06

Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist (2007) 1.85

Ventriculostomy-related infections in critically ill patients: a 6-year experience. J Neurosurg (2005) 1.71

Cardiotonic steroids on the road to anti-cancer therapy. Biochim Biophys Acta (2007) 1.70

3-Aryl-2-quinolone derivatives: synthesis and characterization of in vitro and in vivo antitumor effects with emphasis on a new therapeutical target connected with cell migration. J Med Chem (2002) 1.59

Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med Res Rev (2007) 1.50

Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight. J Med Chem (2009) 1.50

Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res (2010) 1.50

Cell culture processes for monoclonal antibody production. MAbs (2010) 1.48

Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release. J Cell Mol Med (2012) 1.40

Evaluation of the efficiency of chemotherapy in in vivo orthotopic models of human glioma cells with and without 1p19q deletions and in C6 rat orthotopic allografts serving for the evaluation of surgery combined with chemotherapy. Cancer (2002) 1.38

Galectins and cancer. Biochim Biophys Acta (2002) 1.37

Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia (2008) 1.34

Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res (2009) 1.34

Characterization of the activities of actin-affecting drugs on tumor cell migration. Toxicol Appl Pharmacol (2005) 1.28

Naphthalimides and azonafides as promising anti-cancer agents. Curr Med Chem (2009) 1.25

The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia (2007) 1.22

Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery (2008) 1.21

Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice: analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2, ornithine decarboxylase, lung-related resistance protein, prostaglandin E synthetase, and glutathione-S-transferase-alpha (GST)-alpha, GST-mu, and GST-pi. Cancer (2004) 1.21

The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med (2009) 1.21

2,2,2-Trichloro-N-({2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1H-benzo[de]isoquinolin- 5-yl}carbamoyl)acetamide (UNBS3157), a novel nonhematotoxic naphthalimide derivative with potent antitumor activity. J Med Chem (2007) 1.20

4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs. Neoplasia (2007) 1.18

Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther (2006) 1.17

Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia (2010) 1.15

Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer (2003) 1.15

Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia (2006) 1.14

Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol (2002) 1.14

The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia (2008) 1.13

Digital holographic microscopy for the three-dimensional dynamic analysis of in vitro cancer cell migration. J Biomed Opt (2006) 1.12

The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol (2007) 1.11

Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J (2010) 1.10

Autophagy, the Trojan horse to combat glioblastomas. Neurosurg Focus (2006) 1.08

Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents. J Med Chem (2009) 1.08

Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia (2009) 1.07

Na+/K+-ATPase alpha subunits as new targets in anticancer therapy. Expert Opin Ther Targets (2008) 1.07

Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol (2008) 1.06

The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther (2006) 1.05

Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol (2003) 1.05

Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol (2008) 1.05

Videomicroscopic extraction of specific information on cell proliferation and migration in vitro. Exp Cell Res (2008) 1.05

Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer (2003) 1.04

Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1. Immunol Lett (2009) 1.04

Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol (2007) 1.04

Amaryllidaceae alkaloids belonging to different structural subgroups display activity against apoptosis-resistant cancer cells. J Nat Prod (2010) 1.02

Galectins and gliomas. Brain Pathol (2009) 1.01

Evaluation of the antiproliferative activity of diterpene isonitriles from the sponge Pseudoaxinella flava in apoptosis-sensitive and apoptosis-resistant cancer cell lines. J Nat Prod (2011) 1.01

Metabolic flux analysis and pharmaceutical production. Metab Eng (2009) 1.01

Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern. Biochem Biophys Res Commun (2005) 1.00

UNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancers. Neoplasia (2008) 0.99

Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg (2006) 0.99

Therapeutic agents triggering nonapoptotic cancer cell death. J Med Chem (2013) 0.98

111In-oxine and 99mTc-HMPAO labelling of antigen-loaded dendritic cells: in vivo imaging and influence on motility and actin content. Eur J Nucl Med Mol Imaging (2003) 0.98

Anti-galectin compounds as potential anti-cancer drugs. Curr Med Chem (2006) 0.98

Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int J Oncol (2010) 0.98

Up-regulation of galectin-3 and its ligands by Trypanosoma cruzi infection with modulation of adhesion and migration of murine dendritic cells. Glycobiology (2004) 0.98

Galectin 7 (p53-induced gene 1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol (2006) 0.97

Galectin-1 is overexpressed in nasal polyps under budesonide and inhibits eosinophil migration. Lab Invest (2002) 0.97

A model-based approach for automated in vitro cell tracking and chemotaxis analyses. Cytometry A (2004) 0.96

Galectin-1 in melanoma biology and related neo-angiogenesis processes. J Invest Dermatol (2012) 0.96

In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton. Int J Oncol (2002) 0.96

Cimetidine, an unexpected anti-tumor agent, and its potential for the treatment of glioblastoma (review). Int J Oncol (2006) 0.96

Fungal metabolites with anticancer activity. Nat Prod Rep (2014) 0.96